866-997-4948(US-Canada Toll Free)

Axial Spondyloarthritis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 104 Pages

Axial Spondyloarthritis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2017, provides an overview of the Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline landscape.

Axial spondylitis is a type of inflammatory arthritis involving the spine and/or sacroiliac joints. Axial spondylitis is strongly related to the presence of the HLA-B27 gene. A genetic test for HLA-B27 is available.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axial Spondyloarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 1 and 1 respectively.

Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axial Spondyloarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axial Spondyloarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axial Spondyloarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Axial Spondyloarthritis - Overview 6
Axial Spondyloarthritis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 9
Axial Spondyloarthritis - Therapeutics Assessment 10
Assessment by Target 10
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Axial Spondyloarthritis - Companies Involved in Therapeutics Development 18
AstraZeneca Plc 18
Eli Lilly and Co 18
Novartis AG 19
Sandoz International GmbH 19
Sun Pharma Advanced Research Company Ltd 20
UCB SA 20
Axial Spondyloarthritis - Drug Profiles 22
adalimumab biosimilar - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
adalimumab biosimilar - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
brodalumab - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
certolizumab pegol - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
etanercept biosimilar - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ixekizumab - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
secukinumab - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
tildrakizumab - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Axial Spondyloarthritis - Dormant Projects 76
Axial Spondyloarthritis - Product Development Milestones 77
Featured News & Press Releases 77
Jun 27, 2017: Sandoz receives approval in Europe for Erelzi (biosimilar etanercept) to treat multiple inflammatory diseases 77
Jun 14, 2017: Results from CRIB study on CIMZIA (certolizumab pegol) demonstrate minimal to no placental transfer of drug from mother to infant during third trimester of pregnancy 77
Jun 14, 2017: UCB announces four-year imaging results demonstrating low disease progression and long-term efficacy of CIMZIA (certolizumab pegol) in patients with axial spondyloarthritis 79
Apr 24, 2017: Kyowa Hakko Kirin Announces Initiation of Global Phase 3 Study of KHK4827 (Brodalumab) in Patients with Axial Spondyloarthritis (axSpA) 80
Apr 21, 2017: Sandoz Receives CHMP Positive Opinion For Erelzi 80
Mar 06, 2017: First CIMZIA Study of Its Kind Showed Minimal to No Transfer of Drug from Mothers Plasma to Breast Milk 81
Nov 11, 2016: UCB Presents Data on Cimzia (certolizumab pegol) at 2016 ACR/ARHP Annual Meeting 82
Oct 25, 2016: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - a New Self-injection Device Designed in Collaboration With Patients and Good Grips - is Now Available in the UK on the NHS 86
Jun 08, 2016: UCB commitment to addressing real world patient needs on display at the Annual European Congress of Rheumatology (EULAR 2016) 86
Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 89
Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 94
Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 97
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 98
Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 99
Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 101
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104

List of Tables
Number of Products under Development for Axial Spondyloarthritis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Products under Development by Companies, H2 2017 9
Number of Products by Stage and Target, H2 2017 11
Number of Products by Stage and Mechanism of Action, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 17
Axial Spondyloarthritis - Pipeline by AstraZeneca Plc, H2 2017 18
Axial Spondyloarthritis - Pipeline by Eli Lilly and Co, H2 2017 19
Axial Spondyloarthritis - Pipeline by Novartis AG, H2 2017 19
Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H2 2017 20
Axial Spondyloarthritis - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 20
Axial Spondyloarthritis - Pipeline by UCB SA, H2 2017 21
Axial Spondyloarthritis - Dormant Projects, H2 2017 76

List of Figures
Number of Products under Development for Axial Spondyloarthritis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 10
Number of Products by Stage and Targets, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Molecule Types, H2 2017 16
Number of Products by Stage and Molecule Types, H2 2017 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *